| 摘要 |
[Objectives] To evaluate the clinical efficacy and safety of Kunkui Kidney Preserving Paste in the treatment of diabetic kidney disease (DKD) patients with damp-heat stasis syndrome in the clinical proteinuria stage. [Methods] Retrospective analysis was made on 30 patients with DKD who were diagnosed with damp-heat stasis syndrome in the clinical proteinuria stage from March 2021 to March 2023 in Jiangsu Province Hospital of Chinese Medicine, and who took Kunkui Kidney Preserving Paste continuously for six months. The urinary albumin/creatinine ratio (UACR), urinary complement C3, and urea nitrogen (BUN) of DKD patients before and after treatment were compared, and estimated glomerular filtration rate (eGFR), blood creatinine (Scr), and cystatin C (CysC) were estimated, and the therapeutic effects on renal function and urinary protein were evaluated. [Results] After treatment, UACR significantly decreased (P<0.01), and urinary complement C3 and Scr decreased (P<0.05), while other indicators showed no significant statistical difference (P>0.05). In terms of evaluating the efficacy of urinary protein therapy, 8 cases showed recent relief; 8 cases showed significant effect; 9 cases were effective, and 5 cases were invalid after treatment, with a total effective rate of 83.33%. In terms of renal function efficacy evaluation, 8 cases showed significant effect; 4 cases were effective; 11 cases were stable, and 7 cases were invalid, with a total effective rate of 76.67%. In the safety evaluation, there were no obvious adverse reactions. [Conclusions] The Kunkui Kidney Preserving Past has significant clinical efficacy and safety in treating DKD patients with damp-heat stasis syndrome in the clinical proteinuria period. It has significant advantages in reducing urinary protein and protecting renal function, which is worthy of clinical promotion. |
